Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M205Revenue $M1.1Net Margin (%)-3,775.3Z-Score-15.6
Enterprise Value $M210EPS $-0.4Operating Margin %-3,398.6F-Score3
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-3,775.3Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio5.0Cash flow > EarningsY
Price/Sales93.55-y EBITDA Growth Rate %59.1Current Ratio5.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-105.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M151ROI % (ttm)-168.4Gross Margin Increase y-yN

Gurus Latest Trades with NAVB

Number of guru portfolios checked: 56.

No Entry found!

NAVB is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NAVB: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Regan William J.SVP-Global Reg Affairs&Quality 2014-05-12Buy5,000$1.43-4.9 view
PYKETT MARK JEROMECEO 2014-05-09Buy10,000$1.341.49 view
Cope Frederick OSVP 2014-03-10Sell15,000$1.96-30.61 view
LARSON BRENT LEVP, CFO, Treas & Secy 2014-03-10Sell41,500$1.96-30.61 view
PYKETT MARK JEROMECEO 2014-03-10Sell120,000$1.96-30.61 view
FORD BRENDAN ADirector 2013-11-08Buy20,000$1.45-6.21 view
LARSON BRENT LEVP, CFO, Treas & Secy 2013-11-08Buy5,000$1.39-2.16 view
PYKETT MARK JEROMECEO 2013-11-08Buy10,900$1.350.74 view
Cope Frederick OSVP 2013-11-08Buy3,500$1.43-4.9 view
Troup Gordon ADirector 2013-11-08Buy20,000$1.360 view

Press Releases about NAVB :

    Quarterly/Annual Reports about NAVB:

    News about NAVB:

    Articles On GuruFocus.com
    Navidea Biopharmaceuticals Reports 4 Insider Trades Mar 18 2013 
    comment on NAVB Mar 15 2013 

    More From Other Websites
    NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jul 21 2014
    Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results Jul 17 2014
    NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jul 16 2014
    Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment... Jul 16 2014
    Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment... Jul 16 2014
    Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8,... Jul 02 2014
    Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8,... Jul 02 2014
    NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events,... Jun 16 2014
    Navidea confirms FDA approval of expanded use for Lymphoseek Jun 13 2014
    U.S. FDA Approves Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept)... Jun 13 2014
    Biotech Stock Mailbag: Vanda, Navidea, Provectus Jun 13 2014
    Navidea (NAVB) Worth Watching: Stock Up 7.3% Jun 12 2014
    Navidea announces results from post-hoc analysis from Lymphoseek injection trial Jun 11 2014
    Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection Demonstrates... Jun 11 2014
    Navidea Biopharmaceuticals Announces Positive Lymphoseek® (technetium Tc 99m tilmanocept) Injection... Jun 10 2014
    Navidea Announces Data Demonstrating Potential of Manocept™ Platform to Diagnose Rheumatoid... Jun 10 2014
    NAVIDEA BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 02 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide